Aurinia hires EVP of R&D, commercial head and VP of IR
Plus Enveda names Gilead’s Sekar as CBO and Covis hires a Poulin as SVP, general manager
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced three executive appointments. Volker Knappertz is joining the company as EVP of R&D, Scott Habig as chief commercial officer (CCO), and DeDe Sheel as VP of investor relations. Knappertz, a neurologist, was CMO and EVP of R&D at GW Pharmaceuticals plc. Habig was most recently head of global SLE at UCB S.A. (Euronext:UCB), and succeeds current Aurinia CCO Max Colao who is leaving the company for personal reasons. Sheel was VP, investor relations at Sierra Oncology Inc. and Aimmune Therapeutics Inc. In January 2021, FDA approved Aurinia’s first product, Lupkynis voclosporin, to treat lupus nephritis.
Enveda Biosciences Inc. hired Vanitha Sekar as CBO, a newly created role at the machine learning and metabolomics company. Sekar was head of corporate development at Gilead Sciences Inc. (NASDAQ:GILD), before which she was executive director of business development and licensing at Merck & Co. Inc. (NYSE:MRK). ...